Search
argenx SE
ARGXAdd to Watchlist
849.985USD
-3.415-0.40%
Market hours （ET）Quotes delayed by 15 min
52.60BMarket Cap
35.13P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.40%
5 Days
-3.24%
1 Month
+5.40%
6 Months
+0.48%
Year to Date
+1.07%
1 Year
+57.18%
Key Figures
869.850Open
877.120High
287.29KVolume
35.13P/E TTM
22.87P/E Dynamic
--Dividend TTM
0.46%Turnover Ratio
853.400Prev. Close
848.135Low
162.54MTurnover
63.14P/E Static
7.18P/B
0.00%Div Yield TTM
17.36%ROA
934.62052wk High
2.44Volume Ratio
833.04MNet Profit
61.88MShares
24.1978EPS TTM
0.47Beta
20.15%ROE
510.05552wk Low
3.40%Amplitude
90.68%Gross Margin
52.60BMarket Cap
3.76Reward/Risk
1.55%Risk Rate
TradingKey Stock Score of argenx SE
Currency: USD Updated: 2026-06-23Key Insights
argenx SE's fundamentals are relatively stable, and its growth potential is good.Its valuation is considered fairly valued, ranking 83 out of 389 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1052.72.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
argenx SE's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
argenx SE Highlights
StrengthsRisks
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 238.52% year-on-year.
Overvalued
The company’s latest PE is 35.27, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 31.47M shares, decreasing 8.15% quarter-over-quarter.
Held by Frank Sands
Star Investor Frank Sands holds 302.80K shares of this stock.
Analyst Rating
Based on
27
analysts
Buy
Current Rating
1052.724
Target Price
+16.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
argenx SE News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
argenx SE Info
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Ticker SymbolARGX
Companyargenx SE
CEOvan Hauwermeiren (Tim)
Websitehttps://www.argenx.com/
Related Instruments
+0.16%
+0.52%
+1.01%
-0.34%
+0.36%
-0.12%
+1.56%
+0.11%
+0.31%
-1.48%
+1.78%
-0.27%
-1.14%
-0.08%
+1.22%
0.00%
+0.80%
+1.68%
-0.47%Popular Instruments
70.319
-2.626 (-3.60%)
297.935
+3.635 (+1.24%)
200.510
+0.470 (+0.23%)
4006.510
-104.240 (-2.54%)
647.000
-23.750 (-3.54%)
1909.760
-53.840 (-2.74%)
1030.240
-21.530 (-2.05%)
350.965
+4.835 (+1.40%)
60631.360
-1809.340 (-2.90%)
383.228
+1.618 (+0.42%)
FAQs
What is the current price of argenx SE (ARGX)?
The current price of argenx SE (ARGX) is 854.01.
What is the symbol of argenx SE?
The ticker symbol of argenx SE is ARGX.
What is the 52-week high of argenx SE?
The 52-week high of argenx SE is 934.62.
What is the 52-week low of argenx SE?
The 52-week low of argenx SE is 510.06.
What is the market capitalization of argenx SE?
The market capitalization of argenx SE is 57.54B.
Is argenx SE (ARGX) currently rated as Buy, Hold, or Sell?
According to analysts, argenx SE (ARGX) has an overall rating of Buy, with a price target of 1052.72.
What is the Earnings Per Share (EPS TTM) of argenx SE (ARGX)?
The Earnings Per Share (EPS TTM) of argenx SE (ARGX) is 21.08.
